BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22516868)

  • 1. Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
    Cavalli R; Buffon RB; de Souza M; Colli AM; Gelmetti C
    Dermatology; 2012; 224(2):106-9. PubMed ID: 22516868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new treatment pathway for propranolol use in infantile haemangiomas.
    May JE; Liew SH
    J Plast Reconstr Aesthet Surg; 2014 Mar; 67(3):e91-2. PubMed ID: 24268691
    [No Abstract]   [Full Text] [Related]  

  • 3. Ulcerated nasal infantile haemangioma treated by oral propranolol.
    Al Dosari S; Riad H
    Dermatol Online J; 2013 May; 19(5):18298. PubMed ID: 24011285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infantile hemangioma: treatment with short course systemic corticosteroid therapy as an alternative for propranolol.
    Nieuwenhuis K; de Laat PC; Janmohamed SR; Madern GC; Oranje AP
    Pediatr Dermatol; 2013; 30(1):64-70. PubMed ID: 22958179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
    Moyakine AV; Hermans DJ; Fuijkschot J; van der Vleuten CJ
    J Am Acad Dermatol; 2015 Aug; 73(2):341-2. PubMed ID: 26183988
    [No Abstract]   [Full Text] [Related]  

  • 6. Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.
    Kumar MG; Coughlin C; Bayliss SJ
    Pediatr Dermatol; 2015; 32(2):171-9. PubMed ID: 25556828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalemia complicating propranolol treatment of an infantile hemangioma.
    Pavlakovic H; Kietz S; Lauerer P; Zutt M; Lakomek M
    Pediatrics; 2010 Dec; 126(6):e1589-93. PubMed ID: 21115582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.
    Rotter A; Samorano LP; de Oliveira Labinas GH; Alvarenga JG; Rivitti-Machado MC; Bouer M; Santos PC; Silvestre DA; de Oliveira ZN
    Int J Dermatol; 2017 Feb; 56(2):190-194. PubMed ID: 27813086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
    Jacks SK; Kertesz NJ; Witman PM; Fernandez Faith E
    J Am Acad Dermatol; 2015 Aug; 73(2):255-7. PubMed ID: 26054433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS).
    Janmohamed SR; van Oosterhout M; de Laat PC; van Rosmalen J; Madern GC; Oranje AP
    J Am Acad Dermatol; 2015 Aug; 73(2):258-63. PubMed ID: 26183969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol in the management of infantile hemangiomas: clinical response and predictors.
    Balma-Mena A; Chakkittakandiyil A; Weinstein M; Lansang P; Ho N; Cammisuli S; Pope E
    J Cutan Med Surg; 2012; 16(3):169-73. PubMed ID: 22713439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome.
    Schupp CJ; Kleber JB; Günther P; Holland-Cunz S
    Pediatr Dermatol; 2011; 28(6):640-644. PubMed ID: 21995836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years.
    Moyakine AV; Kerstjens JM; Spillekom-van Koulil S; van der Vleuten CJ
    J Am Acad Dermatol; 2016 Jul; 75(1):59-63.e1. PubMed ID: 27021240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence of infantile hemangiomas treated with propranolol.
    Bagazgoitia L; Hernández-Martín Á; Torrelo A
    Pediatr Dermatol; 2011; 28(6):658-662. PubMed ID: 22082463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
    Bellaud G; Puzenat E; Billon-Grand NC; Humbert P; Aubin F
    Int J Dermatol; 2015 Jan; 54(1):102-7. PubMed ID: 24962639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful first-line treatment with propranolol of multifocal infantile hepatic hemangioma with high-flow cardiac overload.
    Sciveres M; Marrone G; Pipitone S; Riva S; Spada M; Gridelli B; Maggiore G
    J Pediatr Gastroenterol Nutr; 2011 Dec; 53(6):693-5. PubMed ID: 21519284
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
    Oksiuta M; Matuszczak E; Dębek W; Dzienis-Koronkiewicz E; Hermanowicz A; Tylicka M
    Postepy Hig Med Dosw (Online); 2014 Sep; 68():1138-44. PubMed ID: 25228522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
    Kim LHC; Hogeling M; Wargon O; Jiwane A; Adams S
    J Pediatr Surg; 2011 Apr; 46(4):759-763. PubMed ID: 21496551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propranolol for treatment of ulcerated infantile hemangiomas.
    Saint-Jean M; Léauté-Labrèze C; Mazereeuw-Hautier J; Bodak N; Hamel-Teillac D; Kupfer-Bessaguet I; Lacour JP; Naouri M; Vabres P; Hadj-Rabia S; Nguyen JM; Stalder JF; Barbarot S;
    J Am Acad Dermatol; 2011 May; 64(5):827-32. PubMed ID: 21353332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
    Mashiah J; Kutz A; Rabia SH; Ilan EB; Goldberg I; Sprecher E; Harel A
    Int J Dermatol; 2017 Feb; 56(2):148-153. PubMed ID: 28074521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.